SCHEMBL718319

SCHEMBL718319

COCc1nn(-c2cc(C(F)(F)F)ccn2)cc1CO

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
ALDH1A1 P00352 2/20 0.35
GAA P10253 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CYP1A2 P05177 2/20 0.35
KDM4E B2RXH2 2/20 0.34
CYP2D6 P10635 1/20 0.34
PPARG P37231 1/20 0.33
PPARD Q03181 1/20 0.33
PPARA Q07869 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
FFAR4 Q5NUL3 1/20 0.33
NOS3 P29474 1/20 0.33
NOS2 P35228 1/20 0.33
MAPT P10636 2/20 0.32
GRM5 P41594 1/20 0.32
EGLN2 Q96KS0 1/20 0.32
NOTUM Q6P988 1/20 0.32
ADRB2 P07550 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27834233 0.83 ADRB1 (0.41) ADRB1NPSR1ALDH1A1GAAL3MBTL1
SCHEMBL719678 0.82 CFTR (0.41) ADRB1NPSR1ALDH1A1GAAL3MBTL1
SCHEMBL719877 0.81 NPSR1 (0.38) ADRB1NPSR1ALDH1A1GAAL3MBTL1
SCHEMBL718365 0.75 PDE2A (0.36) ADRB1NPSR1HRH3FFAR4ADRB2
SCHEMBL718692 0.75 IRAK4 (0.41)
SCHEMBL6035729 0.70 NPSR1 (0.42) ADRB1NPSR1ALDH1A1KDM4ECYP2D6
SCHEMBL1805973 0.70 KDM4E (0.39) NPSR1ALDH1A1GAAL3MBTL1KDM4E
SCHEMBL27852363 0.69 RAB9A (0.56) NPSR1ALDH1A1GAAL3MBTL1KDM4E
SCHEMBL6034456 0.69 L3MBTL1 (0.42) NPSR1ALDH1A1GAAL3MBTL1PPARG
SCHEMBL1806117 0.68 NOTUM (0.46) ALDH1A1GAAKDM4EMAPTNOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP ADRB1 1358/4885NPSR1 2548/4885ALDH1A1 504/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP ADRB1 1358/4885NPSR1 2548/4885ALDH1A1 504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.